{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:01:19Z","timestamp":1770721279002,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1991,11,1]],"date-time":"1991-11-01T00:00:00Z","timestamp":688953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[1991,11]]},"DOI":"10.1007\/bf01741331","type":"journal-article","created":{"date-parts":[[2005,6,13]],"date-time":"2005-06-13T15:28:42Z","timestamp":1118676522000},"page":"364-372","source":"Crossref","is-referenced-by-count":72,"title":["Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody"],"prefix":"10.1007","volume":"32","author":[{"given":"A.","family":"Hekman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Honselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. M. J.","family":"Vuist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Sein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. W.","family":"ten Bokkel Huinink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Somers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ph.","family":"R\u00fcmke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J. M.","family":"Melief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01741331_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4049\/jimmunol.139.3.971","volume":"139","author":"N Berinstein","year":"1987","unstructured":"Berinstein N, Levy R (1987) Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol 139: 971","journal-title":"J Immunol"},{"key":"BF01741331_CR2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood.V68.3.752.752","volume":"69","author":"JH Bertram","year":"1986","unstructured":"Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, Mitchell MS (1986) Monoclonal antibody T 101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood 69: 752","journal-title":"Blood"},{"key":"BF01741331_CR3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V73.3.651.651","volume":"73","author":"SL Brown","year":"1989","unstructured":"Brown SL, Miller RA, Homing SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73: 651","journal-title":"Blood"},{"key":"BF01741331_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0145-2126(88)90073-2","volume":"12","author":"MA Rie De","year":"1988","unstructured":"De Rie MA, Zeijlemaker WP, Von dem Borne AEGKr (1988) Inhibition by vinca alkaloids and colchicine of antigenic modulation induced by anti-CD19 monoclonal antibodies. Leukemia Res 12: 135","journal-title":"Leukemia Res"},{"key":"BF01741331_CR5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0008-8749(89)90385-7","volume":"118","author":"MA Rie De","year":"1989","unstructured":"De Rie MA, Schumacher TNM, Van Schijndel GMW, Van Lier RAW, Miedema F (1989) Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol 118: 368","journal-title":"Cell Immunol"},{"key":"BF01741331_CR6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.V73.6.1431.1431","volume":"73","author":"MJS Dyer","year":"1989","unstructured":"Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431","journal-title":"Blood"},{"key":"BF01741331_CR7","first-page":"2771","volume":"47","author":"A Eisenthal","year":"1987","unstructured":"Eisenthal A, Lafreniere R. Lefor AT, Rosenberg SA (1987) Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47: 2771","journal-title":"Cancer Res"},{"key":"BF01741331_CR8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0091-6749(89)90176-0","volume":"85","author":"WJ Fokkens","year":"1989","unstructured":"Fokkens WJ, Vroom ThM, Rijntjes E, Mulder PGH (1989) Fluctuation of the number of CD-1(T6)-positive dendritic cells, presumably Langerhans cells, in the nasal mucosa of patients with an isolated grass-pollen allergy before, during and after the grass-pollen season. J Allerg Clin Immunol 85: 39","journal-title":"J Allerg Clin Immunol"},{"key":"BF01741331_CR9","first-page":"1621","volume":"49","author":"KA Foon","year":"1989","unstructured":"Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621","journal-title":"Cancer Res"},{"key":"BF01741331_CR10","first-page":"139","volume":"ii","author":"G Hale","year":"1984","unstructured":"Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H (1984) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet ii: 139","journal-title":"Lancet"},{"key":"BF01741331_CR11","first-page":"180","volume":"16","author":"DT Harris","year":"1989","unstructured":"Harris DT, Mastrangelo MJ (1989) Serotherapy of cancer. Semin Oncol 16: 180","journal-title":"Semin Oncol"},{"key":"BF01741331_CR12","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1073\/pnas.83.20.7893","volume":"83","author":"CJ Honsik","year":"1986","unstructured":"Honsik CJ, Jung G, Reisfeld RA (1986) Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 83: 7893","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF01741331_CR13","first-page":"1173","volume":"48","author":"I Kawase","year":"1988","unstructured":"Kawase I, Komuta K, Hara H, Inoue I, Hosoe S, Ikeda T, Shirasaka T, Yokota T, Tanio Y, Masuno T, Kishimoto S (1988) Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 48: 1173","journal-title":"Cancer Res"},{"key":"BF01741331_CR14","volume-title":"Leucocyte typing IV, 4th international workshop and conference on human leucocyte differentiation antigens, Vienna 1989","year":"1989","unstructured":"Knapp W, D\u00f6rken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, Von dem Borne AEGKr (eds) (1989) Leucocyte typing IV, 4th international workshop and conference on human leucocyte differentiation antigens, Vienna 1989, Oxford University Press, Oxford"},{"key":"BF01741331_CR15","first-page":"359","volume":"4","author":"JN Lowder","year":"1985","unstructured":"Lowder JN, Meeker TC, Levy R (1985) Monoclonal antibody therapy of lymphoid malignancy. Cancer Surv 4: 359","journal-title":"Cancer Surv"},{"key":"BF01741331_CR16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","volume":"65","author":"TC Meeker","year":"1985","unstructured":"Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65: 1349","journal-title":"Blood"},{"key":"BF01741331_CR17","first-page":"2773","volume":"49","author":"AC Morgan","year":"1989","unstructured":"Morgan AC, Sullivan W, Graves S, Woodhouse CS (1989) Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2. Cancer Res 49: 2773","journal-title":"Cancer Res"},{"key":"BF01741331_CR18","first-page":"6600","volume":"47","author":"DH Munn","year":"1987","unstructured":"Munn DH, Cheung N-KV (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47: 6600","journal-title":"Cancer Res"},{"key":"BF01741331_CR19","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.138.10.3566","volume":"138","author":"JR Ortaldo","year":"1987","unstructured":"Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R (1987) Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 138: 3566","journal-title":"J Immunol"},{"key":"BF01741331_CR20","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.4049\/jimmunol.138.9.2793","volume":"138","author":"A Pezzutto","year":"1987","unstructured":"Pezzutto A, D\u00f6rken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA (1987) CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 138: 2793","journal-title":"J Immunol"},{"key":"BF01741331_CR21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"OW Press","year":"1987","unstructured":"Press OW, Appelbaum F, Ledbetter JA, Marin PJ, Zarlin J, Kidd P, Thomas ED (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69: 584","journal-title":"Blood"},{"key":"BF01741331_CR22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","volume":"7","author":"OW Press","year":"1989","unstructured":"Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSanted K, Porter B, Kidd P, Thomas ED, Bernstein ID (1989) Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7: 1027","journal-title":"J Clin Oncol"},{"key":"BF01741331_CR23","first-page":"4906","volume":"49","author":"OW Press","year":"1989","unstructured":"Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B cell malignancies. Cancer Res 49: 4906","journal-title":"Cancer Res"},{"key":"BF01741331_CR24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/eji.1830141211","volume":"14","author":"EM Rankin","year":"1984","unstructured":"Rankin EM, Hekman A (1984) Mouse monoclonal antibodies against the idiotype of human B cell non-Hodgkin lymphomas: production, characterization and use to monitor the progress of disease. Eur J Immunol 14: 1119","journal-title":"Eur J Immunol"},{"key":"BF01741331_CR25","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V65.6.1373.bloodjournal6561373","volume":"65","author":"EM Rankin","year":"1985","unstructured":"Rankin EM, Hekman A, Somers R, Ten Bokkel Huinink W (1985) Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood 65: 1373","journal-title":"Blood"},{"key":"BF01741331_CR26","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.4049\/jimmunol.138.6.1992","volume":"138","author":"E Shiloni","year":"1987","unstructured":"Shiloni E, Eisenthal A, Sachs D, Rosenberg SA (1987) Antibody\u2014dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138: 1992","journal-title":"J Immunol"},{"key":"BF01741331_CR27","first-page":"49","volume":"18","author":"ICM Slaper-Cortenbach","year":"1990","unstructured":"Slaper-Cortenbach ICM, Admiraal LG, Van Leeuwen EF, Kerr JM, Von dem Borne AEGKr, Tetteroo PAT (1990) Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis. Exp Hematol 18: 49","journal-title":"Exp Hematol"},{"key":"BF01741331_CR28","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.85.22.8603","volume":"85","author":"FM Uckun","year":"1988","unstructured":"Uckun FM, Ledbetter JA (1988) Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci USA 85: 8603","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF01741331_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","volume":"71","author":"FM Uckun","year":"1988","unstructured":"Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Pecszalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immuno-toxins. Blood 71: 13","journal-title":"Blood"},{"key":"BF01741331_CR30","first-page":"3783","volume":"49","author":"WMJ Vuist","year":"1989","unstructured":"Vuist WMJ, Van Buitenen F, De Rie MA, Hekman A, R\u00fcmke P, Melief CJM (1989) Potentiation by interleukin-2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xeno-transplantation model. Cancer Res 49: 3783","journal-title":"Cancer Res"},{"key":"BF01741331_CR31","unstructured":"WHO handbook for reporting results of cancer treatment. WHO Offset Publ. no 48, Geneva, WHO 1979"},{"key":"BF01741331_CR32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0167-5699(87)90018-1","volume":"8","author":"H Zola","year":"1987","unstructured":"Zola H (1987) The surface antigens of human B lymphocytes. Immunol Today 8: 308","journal-title":"Immunol Today"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01741331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01741331\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01741331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T19:11:29Z","timestamp":1706296289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01741331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1991,11]]}},"alternative-id":["BF01741331"],"URL":"https:\/\/doi.org\/10.1007\/bf01741331","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,11]]}}}